GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 4SC AG (GREY:FSCGF) » Definitions » COGS-to-Revenue

4SC AG (4SC AG) COGS-to-Revenue : -0.04 (As of Dec. 2023)


View and export this data going back to 2008. Start your Free Trial

What is 4SC AG COGS-to-Revenue?

4SC AG's Cost of Goods Sold for the six months ended in Dec. 2023 was $-0.01 Mil. Its Revenue for the six months ended in Dec. 2023 was $0.19 Mil.

4SC AG's COGS to Revenue for the six months ended in Dec. 2023 was -0.04.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. 4SC AG's Gross Margin % for the six months ended in Dec. 2023 was 104.15%.


4SC AG COGS-to-Revenue Historical Data

The historical data trend for 4SC AG's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

4SC AG COGS-to-Revenue Chart

4SC AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
COGS-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.16 0.23 0.03 0.35 0.31

4SC AG Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.86 0.71 0.11 0.80 -0.04

4SC AG COGS-to-Revenue Calculation

4SC AG's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0.104 / 0.332
=0.31

4SC AG's COGS to Revenue for the quarter that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=-0.008 / 0.193
=-0.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


4SC AG  (GREY:FSCGF) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

4SC AG's Gross Margin % for the six months ended in Dec. 2023 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - -0.008 / 0.193
=104.15 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


4SC AG COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of 4SC AG's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


4SC AG (4SC AG) Business Description

Traded in Other Exchanges
Address
Fraunhoferstraße 22, Planegg-Martinsried, DEU, 82152
4SC AG is a clinical-stage biopharmaceutical company developing small-molecule drugs that can target key indications in cancer with high unmet medical needs. Its pipeline is protected by a comprehensive portfolio of patents and currently comprises two drug candidates in clinical development resminostat and Domatinostat. It Geographic area of the company is Germany, the EU, and Other countries, and the majority of the revenue comes from Other Countries.

4SC AG (4SC AG) Headlines

From GuruFocus

Q1 2020 4Sc AG Earnings Call Transcript

By GuruFocus Research 03-08-2024

Q2 2020 4Sc AG Earnings Call Transcript

By GuruFocus Research 03-08-2024

Q2 2019 4Sc AG Earnings Call (German) Transcript

By GuruFocus Research 03-08-2024

Q1 2021 4Sc AG Earnings Call Transcript

By GuruFocus Research 03-08-2024

Half Year 2021 4Sc AG Earnings Call Transcript

By GuruFocus Research 03-08-2024

Q3 2019 4Sc AG Earnings Call Transcript

By GuruFocus Research 03-08-2024

Q3 2023 4Sc AG Earnings Call Transcript

By GuruFocus Research 03-08-2024

Q2 2022 4Sc AG Earnings Call Transcript

By GuruFocus Research 03-08-2024